Biocells (Beijing) Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Series B2
- Investors
-
8
Biocells (Beijing) General Information
Description
Developer of tumor immunotherapy technologies designed to assist cancer patients in their treatment. The company's technologies focus on the field of neurological diseases and are aimed at biological treatment of tumors and nerves and prevention of strokes, hemorrhagic stroke and cerebral edema, providing cancer patients with immune cell therapy that aids in reducing post-operative recurrence, extending tumor-bearing survival, and lessening the discomfort of radiotherapy and chemotherapy.
Contact Information
Website
www.biocells.cnCorporate Office
- Room 301, 3rd Floor, Building 5, No. 23 Tianrong Street, Daxing Biomedicine Industry Base
- Zhongguancun Science Park, Daxing District
- Beijing, 102629
- China
Corporate Office
- Room 301, 3rd Floor, Building 5, No. 23 Tianrong Street, Daxing Biomedicine Industry Base
- Zhongguancun Science Park, Daxing District
- Beijing, 102629
- China
Biocells (Beijing) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B2) | 16-Jul-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B1) | 15-Sep-2023 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 20-Jul-2023 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series A) | 18-Sep-2021 | Completed | Clinical Trials - General | |||
| 3. Secondary Transaction - Private | 18-May-2021 | Completed | Clinical Trials - General | |||
| 2. Later Stage VC | 26-Jun-2019 | Completed | Clinical Trials - General | |||
| 1. Later Stage VC | 23-Feb-2018 | Completed | Clinical Trials - General |
Biocells (Beijing) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
Biocells (Beijing) Patents
Biocells (Beijing) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026086901-A1 | Polypeptide pharmaceutical composition for treating nervous system diseases and use thereof | Pending | 25-Oct-2024 | ||
| WO-2026001614-A1 | Sulfonylurea compound and use thereof | Pending | 26-Jun-2024 | ||
| AU-2024412128-A1 | Pharmaceutically acceptable salt of polypeptide and use thereof | Pending | 27-Dec-2023 | ||
| EP-4834916-A1 | Pharmaceutically acceptable salt of polypeptide and use thereof | Pending | 27-Dec-2023 | ||
| WO-2025139301-A1 | Pharmaceutically acceptable salt of polypeptide and use thereof | Inactive | 27-Dec-2023 | C07K7/08 |
Biocells (Beijing) Signals
Biocells (Beijing) Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Orinno Capital | Venture Capital | Minority | ||
| Green Pine Capital Partners | Venture Capital | Minority | ||
| San Nuo Technology | Corporation | Minority | ||
| Xiamen Hi-Tech Innovation Center | Venture Capital | Minority | ||
| Everbright Financial Holding Asset Management | Corporate Venture Capital | Minority |
Biocells (Beijing) FAQs
-
When was Biocells (Beijing) founded?
Biocells (Beijing) was founded in 2009.
-
Where is Biocells (Beijing) headquartered?
Biocells (Beijing) is headquartered in Beijing, China.
-
What is the size of Biocells (Beijing)?
Biocells (Beijing) has 30 total employees.
-
What industry is Biocells (Beijing) in?
Biocells (Beijing)’s primary industry is Drug Discovery.
-
Is Biocells (Beijing) a private or public company?
Biocells (Beijing) is a Private company.
-
What is Biocells (Beijing)’s current revenue?
The current revenue for Biocells (Beijing) is .
-
Who are Biocells (Beijing)’s investors?
Orinno Capital, Green Pine Capital Partners, San Nuo Technology, Xiamen Hi-Tech Innovation Center, and Everbright Financial Holding Asset Management are 5 of 8 investors who have invested in Biocells (Beijing).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process